Gynesonics
604 Fifth Avenue
Suite D
Redwood City
California
94063
United States
Tel: 650-216-3860
Fax: 650-299-1566
Website: http://www.gynesonics.com/
Email: info@gynesonics.com
52 articles about Gynesonics
-
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
1/2/2024
Gynesonics®, Inc. announced that with the support of the American College of Obstetrics and Gynecology, the American Medical Association has established a new Current Procedural Terminology Category I code, 58580, for transcervical uterine fibroid ablation with ultrasound guidance using radiofrequency.
-
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
10/17/2023
Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.
-
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids is Now Covered by UnitedHealthcare
8/1/2023
Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is please to announce that its Sonata® Procedure is now covered by UnitedHealthcare, effective August 1, 2023.
-
Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization
4/11/2023
Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Skip Baldino was appointed in early March to the role of President and Chief Executive Officer of the company.
-
Gynesonics Names Robert Brown Chief Financial Officer
9/29/2021
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Robert Brown has joined the company as Chief Financial Officer, starting immediately.
-
Gynesonics Announces FDA Clearance of Next Generation Sonata System
9/16/2021
The Only Transcervical, Incisionless System for Radiofrequency Ablation of Fibroids Provides New Benefits through Features Such as Increased Range of Ablation Sizes, a New User Interface, and Validation of Additional Low Temperature Hospital Reprocessing Systems
-
Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids
4/8/2021
The analysis shows that fibroids, which are often treated by hysteroscopic resection or morcellation, can be effectively treated with the Sonata ® System, the only incision-free, transcervical procedure that can treat most submucous, intramural, subserous, transmural and large fibroids
-
Gynesonics Appoints Susan Stimson to Its Board of Directors
3/18/2021
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Susan Stimson has been appointed as an independent member to the company's Board of Directors.
-
Gynesonics Announces Positive Payer Coverage Issued by Health Care Service Corporation (HCSC) for the Sonata Treatment
3/15/2021
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Health Care Service Corporation (HCSC) has released a coverage policy for The Sonata® Procedure.
-
Gynesonics Announces That Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, A New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids
1/21/2021
Detroit Medical Center’s Danny Benjamin, M.D., FACOG, Chief of Obstetrics and Gynecology at DMC Huron Valley-Sinai Hospital, is the first to provide the uterus-preserving, outpatient treatment option to women in Michigan
-
Sonata, A New Innovative, Incision-Free Treatment For Symptomatic Uterine Fibroids, Has Been Introduced In The MedStar Health System
12/21/2020
MedStar Health is the first health system to provide Sonata, an incision-free, uterus-preserving, outpatient treatment option for women in the Maryland and Washington D.C. area
-
Sonata, a New Innovative, Incision-Free Procedure to Treat Symptomatic Uterine Fibroids, Expands in New York Area
10/27/2020
Treatment provides women with a uterus-preserving, incision-free, outpatient option with significant symptom relief and fast recovery
-
Gynesonics Announces Publication of Long Term Three-Year Results of the SONATA FDA IDE Pivotal Trial
10/13/2020
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of its peer reviewed journal article, “Three-Year Results of the SONATA Pivotal Trial of Transcervical Fib
-
Gynesonics Introduces Sonata in Prominent New York City Fibroid Center
9/22/2020
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today its Sonata® System will be offered by surgeons at Mount Sinai Health System to women in New York City. Mount Sinai is the first center
-
Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes The First In Massachusetts To Offer Innovative New Procedure To Treat Symptomatic Uterine Fibroids
9/3/2020
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Brigham and Women’s Faulkner Hospital is the first provider in Massachusetts to offer the Sonata® System as a treatment for symptomatic u
-
Gynesonics Announces Publication of OPEN Clinical Trial Results, Demonstrating No Intrauterine Adhesion Formation Following Treatment with the Sonata System
8/20/2020
Clinical Study Demonstrates No Adhesion Formation at Second-Look Hysteroscopy Performed Six Weeks After Transcervical Fibroid Ablation with the Sonata System REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of the OPEN clinical trial results, demonstrating a lack of intrauterine adhesion formation af
-
Medical Device Executive Nelson Whistance Joins Gynesonics As Vice President of U.S. Sales
8/17/2020
Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Nelson Whistance has been named Vice President of U.S. Sales. Mr. Whistance reports directly to the President and CEO, Christopher M. Owens. “Nelson is a proven sales leader that has spent the majority of his medical device career dri
-
Gynesonics Announces Publication of CHOICES: A Comparative Study of the Sonata Treatment VERSUS Myomectomy
6/30/2020
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the peer reviewed publication of CHOICES, a comparative, case-matched healthcare economic study.
-
Sonata System Assists Facilities Impacted by the COVID-19 Pandemic in Restarting Elective Gynecologic Procedures
6/22/2020
Positive Aspects of Transcervical Fibroid Ablation, Strong Clinical Results, Provides Facilities with Confidence in Treating Fibroids and Minimizing Potential Viral Risks – Procedural Volumes Increasing
-
Gynesonics Announces Publications on Healthcare Economic Analyses Demonstrating Significant Facility and Payer Cost Savings When Performing the Sonata Treatment Compared to Hysterectomy and Myomectomy for Symptomatic Fibroids
6/4/2020
Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of healthcare economics studies INSPIRE and COMPARE